普健生物(武汉)科技有限公司

首页 产品目录 产品目录(简版) 公司动态 企业认证 企业体检 公司相册 联系我们

武汉艾必赛生物有限公司推荐Recombinant FMDV (SAT-1) VP4 Protein, N-His, 精品蛋白

发布人:普健生物(武汉)科技有限公司

发布日期:2026/4/21 16:44:09

链接:https://www.abinscience.cn/product/78/55017.html

名称:Recombinant FMDV (SAT-1) VP4 Protein, N-His

Accession号:A0A7L4XQ62

货号:VK164032

种属:Foot-and-mouth disease virus SAT 1

表达系统:E. coli

状态:Lyophilized

纯度:>90% as determined by SDS-PAGE.

蛋白长度:Gly200-Ala284

应用:ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

预测分子量:37.01 kDa

用途范围:仅用于科研

储存:Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

 

产品介绍:近期,我国首次发生输入性南非1型(SAT1)口蹄疫疫情,该血清型为非洲特有毒株,与我国长期流行的 O 型、A 型、亚洲 1 型等毒株在基因组、衣壳结构、抗原蛋白组成及表位构象上存在本质区别,不同血清型间无交叉免疫保护,现有常规疫苗无法提供有效保护。

 

Recombinant FMDV (SAT-1) VP4 Protein, N-His是武汉艾必赛生物科技有限公司推出的一款高纯度、高活性的重组蛋白。该蛋白靶向口蹄疫病毒(SAT-1型)的VP4衣壳蛋白,是病毒颗粒结构的关键组分,在病毒组装、稳定性和感染过程中扮演重要角色。本品采用大肠杆菌(E. coli) 表达系统制备,带有N端His标签,便于纯化与检测,经SDS-PAGE验证纯度超过90%,预测分子量约为37.01 kDa。该蛋白已严格验证适用于酶联免疫吸附试验(ELISA)、免疫原制备、SDS-PAGE、Western Blot等多种前沿实验技术。其重组表达形式保证了蛋白的一致性与批间稳定性,是研究口蹄疫病毒结构、致病机制、疫苗开发及诊断试剂研制的理想工具试剂。

 

 

产品购买联系方式:027-87433958/17302791434

邮箱:info@abinscience.com

图片.png

 

参考文献:

Development of two rapid lateral flow test strips for detection of foot-and-mouth disease virus SAT 1 and SAT 3. PMID: 32898572


Unrecognized circulation of SAT 1 foot-and-mouth disease virus in cattle herds around Queen Elizabeth National Park in Uganda. PMID: 26739166


Development of vaccines toward the global control and eradication of foot-and-mouth disease. PMID: 21434805


Development of reverse-transcriptase, real-time PCR assays to distinguish the Southern African Territories (SAT) serotypes 1 and 3 and topotype VII of SAT2 of Foot-and-Mouth Disease Virus. PMID: 36204292


Phylogenomics and molecular evolution of foot-and-mouth disease virus. PMID: 21448588


Genome Sequences of Four Foot-and-Mouth Disease Virus SAT 1 Topotype X Isolates from Cameroon. PMID: 31806747


Seroprevalence of foot-and-mouth disease virus in cattle herds raised in Maasai Mara ecosystem in Kenya. PMID: 32105863


Spatial pattern of foot-and-mouth disease virus serotypes in North Central Nigeria. PMID: 28507418


Foot-and-mouth disease virus serotype SAT1 in cattle, Nigeria. PMID: 28224715


The role of African buffalos (Syncerus caffer) in the maintenance of foot-and-mouth disease in Uganda. PMID: 21143994


Differentiation of the seven serotypes of foot-and-mouth disease virus by reverse transcriptase polymerase chain reaction. PMID: 9274816


Simple and rapid lateral-flow assay for the detection of foot-and-mouth disease virus. PMID: 19726619


Characterisation of recent foot-and-mouth disease viruses from African buffalo (Syncerus caffer) and cattle in Kenya is consistent with independent virus populations. PMID: 25644407


First confirmation of foot and mouth disease virus serotype SAT-1 in cattle and small ruminants in Ethiopia in 2007/08. PMID: 23250672


Foot-and-mouth disease virus detection on a handheld real-time polymerase chain reaction platform. PMID: 31077564


Meta-analysis of genetic diversity of VP1 gene of foot and mouth disease virus serotypes prevalent in Bangladesh from 2010 to 2024. PMID: 41043698


Study on seroprevalence and serotyping of foot and mouth disease in Chad. PMID: 30964458


Characterization of foot-and-mouth disease viruses (FMDVs) from Ugandan cattle outbreaks during 2012-2013: evidence for circulation of multiple serotypes. PMID: 25664876


Serological and phylogenetic characterization of foot and mouth disease viruses from Uganda during cross-sectional surveillance study in cattle between 2014 and 2017. PMID: 31127983


Efficacy of a foot-and-mouth disease vaccine against a heterologous SAT1 virus challenge in goats. PMID: 32312581


Temporal and Spatial Patterns and a Space-Time Cluster Analysis of Foot-and-Mouth Disease Outbreaks in Ethiopia from 2010 to 2019. PMID: 35891538


Molecular Characterization of Foot-and-Mouth Disease Viruses Collected in Tanzania Between 1967 and 2009. PMID: 24460931


Within-Host Viral Growth and Immune Response Rates Predict Foot-and-Mouth Disease Virus Transmission Dynamics for African Buffalo. PMID: 39008835


Evaluation of the solid phase competition ELISA for detecting antibodies against the six foot-and-mouth disease virus non-O serotypes. PMID: 22561986


Differential Persistence of Foot-and-Mouth Disease Virus in African Buffalo Is Related to Virus Virulence. PMID: 26962214


Mutation pressure shapes codon usage in the GC-Rich genome of foot-and-mouth disease virus. PMID: 17768673


Effective Diagnosis of Foot-And-Mouth Disease Virus (FMDV) Serotypes O and A Based on Optical and Electrochemical Dual-Modal Detection. PMID: 34198783


A Simplified mAb-Based Antigen Detection Assay for Rapid Serotyping of Foot-and-Mouth Disease Virus. PMID: 40573352


Crystal structure of the 3C protease from Southern African Territories type 2 foot-and-mouth disease virus. PMID: 27168976


Serological profile of foot-and-mouth disease in wildlife populations of West and Central Africa with special reference to Syncerus caffer subspecies. PMID: 26156024


Genetic heterogeneity in the foot-and-mouth disease virus Leader and 3C proteinases. PMID: 12036580


Foot-and-mouth disease virus serotypes detected in Tanzania from 2003 to 2010: conjectured status and future prospects. PMID: 23327382


Investigation of foot-and-mouth disease outbreaks in the Mbala and Kazungula districts of Zambia. PMID: 25134173


Antibodies against foot-and-mouth disease (FMD) virus in African buffalos (Syncerus caffer) in selected National Parks in Uganda (2001-2003). PMID: 20561289


Analysis of synonymous codon usage in foot-and-mouth disease virus. PMID: 20425142

 

 

详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司
官方网址:【中文】https://www.abinscience.cn

【英文】https://www.abinscience.com



武汉艾必赛生物技术有限公司成立于 2023 年,是 abinScience 在亚洲地区设立的官方全资子公司,全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。

依托严格的产品研发体系和国际化的质量管理标准,武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作,现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系,面向区域内科研机构、高校实验室与生物医药企业,提供稳定、高效、可信赖的产品与服务。

核心业务覆盖:
✅ 抗体产品(单抗、多抗、重组抗体等)
✅ 蛋白与多肽试剂(标签蛋白、功能蛋白等)
✅ 分子与细胞实验相关耗材
✅ 定制化研发服务(蛋白表达、抗体定制、亲和力成熟等)
✅ 科研供应链整合与项目配套支持

武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念,为亚太地区的生命科学研究持续注入高质量动能。

 

相关新闻资讯

宠物精准靶向治疗|六大疾病核心靶点与新临床药物全解析

2026/04/22

宠物医学正迎来精准靶向时代,从过敏瘙痒到肿瘤免疫逃逸,再到慢性肾病和骨关节炎,已锁定多个核心分子靶点。本文按疾病类别系统整理了常见宠物疾病和关键治疗靶点以及研究进展。1、过敏性/皮肤疾病核心症状:剧烈瘙痒(pruritus)是犬特应性皮炎最突出临床表现,常表现为持续抓挠、舔咬、摩擦,导致局部皮肤红肿、丘疹、渗出,甚至苔藓化(lichenification)。长期抓挠易继发细菌或酵母菌感染(如马拉色

【经销商招募】 abinScience 携手共赢 助力成长

2026/04/21

武汉艾必赛生物技术有限公司成立于2023年,是Abinscience在亚洲地区的官方全资子公司,主要负责Abinscience品牌在亚太市场的科研试剂推广、销售及技术支持工作。公司依托严格的研发体系和成熟的国际合作平台,与ProteoGenix品牌保持稳定合作,为区域内科研机构和医药企业提供高质量产品及专业服务。 渠道优势支持体系培训支持定期开展线上及线下培训,提升合作伙伴的产品知识及市场推广能力

从Rocatinlimab全球临床终止,看OX40靶点的基础研究边界与转化挑战

2026/04/20

2026年3月3日,日本协和麒麟(Kyowa Kirin)发布官方公告,宣布立即终止OX40靶向单克隆抗体Rocatinlimab的全部全球临床试验。此前,该药物的全球合作开发方安进(Amgen),已于2026年2月以战略优先级调整为由,将Rocatinlimab的全球开发权全部退回协和麒麟。作为全球推进至多项III期临床的OX40阻断型抗体,Rocatinlimab核心适应症覆盖中重度特